In September 2010, trachea transplant surgeon Paolo Macchiarini was basically at the end of his career of fraud and patient abuse, unwanted by everyone. Except by Karolinska Institutet in Sweden, which pushed the recruitment process through in just 3 weeks, despite warnings from colleagues in Florence, Barcelona and Hannover not to employ someone who was basically a lying psychopath. Yet Karolinska leadership was desperate for some positive reviews for Macchiarini. They finally got them from London, from UCL and GOSH.
The Paolo Macchiarini investigation was initiated in 2016 by the interim Karolinska Rector Karin Dahlman-Wright, finalised this year by the newly installed Ole Petter Ottersen. The irony is that several Dahlman-Wright papers were now scrutinised data integrity sleuths with the result that one wonders if Dahlman-Wright was the right person to supervise any research misconduct investigations. Also Ottersen himself might be tainted: he is co-author on an old paper with image duplication.
In the aftermath of the scandal around Paolo Macchiarini, which left many patients dead, his former employer Karolinska Institutet requested a retraction a paper. The Swiss-German medical publisher Karger and its journal Respiration however categorically refused and ordered KI not “to patronize the readers of the journal ‘Respiration’.” The German Editor-in-Chief had namely a huge conflict of interest.
The predatory conferences organised by Ashutosh Tiwari became now a comparatively modest affair. Tiwari stopped pretending being a LiU professor and even ceased signing his conference invitations. Internet announcements for his conference scams became rather minimalistic, while conference programmes or lists of speakers are not released to participants and are apparently arranged on the spot.
Swedish start-up Verigraft received €2.2 Million from European Union, to further develop regenerative medicine technology tainted by research misconduct and patient abuse. The founder of this very company: Suchitra Sumitran-Holgersson. A clinical trial is scheduled based on debunked science of recellurising dead blood vessel grafts.